Rohto Pharmaceutical (TYO:4527) has set a sales target of 464 billion yen for fiscal 2032 under its updated long-term growth strategy, according to a Tokyo bourse filing on Friday.

Other goals for the fiscal year include operating profit of 59.8 billion yen, operating profit margin of 12.9%, an overseas sales ratio of 56% and a dividend payout ratio of 40%.

For fiscal 2031, the company updated its targets to 444 billion yen in sales, 56.8 billion yen in operating profit, 12.8% in operating profit margin and 18% in EBITDA margin.